• Explore /
  • Poster
  • / The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.

The outcome and toxicity profile of checkpoint inhibitor immunotherapy subsequent to high-dose IL-2 in the treatment of metastatic melanoma and renal cell carcinoma.

Abstract Poster

Authors

Stephanie Berg

Stephanie A. Berg

Loyola University Health Sysem, Maywood, IL

Stephanie A. Berg, Joseph I. Clark, Elizabeth Henry, Courtney Regan Wagner, Robert Charles Flanigan, Hanh P. Mai

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Citation

J Clin Oncol 37, 2019 (suppl 8; abstr 14)

DOI

10.1200/JCO.2019.37.8_suppl.14

Abstract #

14

Poster Bd #

A7

Abstract Disclosures

Similar Posters

First Author: Jennifer O'Neil

First Author: Gregory A. Daniels

First Author: Rongsu Qi

First Author: Shannon Neville Westin